MSK
Search
- Page Path
- HOME > Search
Journal Articles
- Eradication of drug-resistant Acinetobacter baumannii by cell-penetrating peptide fused endolysin
- Jeonghyun Lim , Jaeyeon Jang , Heejoon Myung , Miryoung Song
- J. Microbiol. 2022;60(8):859-866. Published online May 25, 2022
- DOI: https://doi.org/10.1007/s12275-022-2107-y
- 61 View
- 0 Download
- 10 Web of Science
- 9 Crossref
-
Abstract
- Antimicrobial agents targeting peptidoglycan have shown successful results in eliminating bacteria with high selective toxicity. Bacteriophage encoded endolysin as an alternative antibiotics is a peptidoglycan degrading enzyme with a low rate of resistance. Here, the engineered endolysin was developed to defeat multiple drug-resistant (MDR) Acinetobacter baumannii. First, putative endolysin PA90 was predicted by genome analysis of isolated Pseudomonas phage PBPA. The His-tagged PA90 was purified from BL21(DE3) pLysS and tested for the enzymatic activity using Gram-negative pathogens known for having a high antibiotic resistance rate including A. baumannii. Since the measured activity of PA90 was low, probably due to the outer membrane, cell-penetrating peptide (CPP) DS4.3 was introduced at the N-terminus of PA90 to aid access to its substrate. This engineered endolysin, DS-PA90, completely killed A. baumannii at 0.25 μM, at which concentration PA90 could only eliminate less than one log in CFU/ml. Additionally, DS-PA90 has tolerance to NaCl, where the ~50% of activity could be maintained in the presence of 150 mM NaCl, and stable activity was also observed with changes in pH or temperature. Even MDR A. baumannii strains were highly susceptible to DS-PA90 treatment: five out of nine strains were entirely killed and four strains were reduced by 3–4 log in CFU/ml. Consequently, DS-PA90 could protect waxworm from A. baumannii-induced death by ~70% for ATCC 17978 or ~44% for MDR strain 1656-2 infection. Collectively, our data suggest that CPP-fused endolysin can be an effective antibacterial agent against Gramnegative pathogens regardless of antibiotics resistance mechanisms.
-
Citations
Citations to this article as recorded by
- Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model
Jeonghyun Lim, Heejoon Myung, Daejin Lim, Miryoung Song
Journal of Biomedical Science.2024;[Epub] CrossRef - Tissue damage alleviation and mucin inhibition by P5 in a respiratory infection mouse model with multidrug-resistant Acinetobacter baumannii
Jun Hee Oh, Jonggwan Park, Hee Kyoung Kang, Hee Joo Park, Yoonkyung Park
Biomedicine & Pharmacotherapy.2024; 181: 117724. CrossRef - Potential of antimicrobial peptide-fused endolysin LysC02 as therapeutics for infections and disinfectants for food contact surfaces to control Cronobacter sakazakii
Doyeon Kim, Jinwoo Kim, Minsik Kim
Food Control.2024; 157: 110190. CrossRef - Gram-negative endolysins: overcoming the outer membrane obstacle
Hazel M Sisson, Simon A Jackson, Robert D Fagerlund, Suzanne L Warring, Peter C Fineran
Current Opinion in Microbiology.2024; 78: 102433. CrossRef - LysJEP8: A promising novel endolysin for combating multidrug‐resistant Gram‐negative bacteria
Jose Vicente Carratalá, Neus Ferrer‐Miralles, Elena Garcia‐Fruitós, Anna Arís
Microbial Biotechnology.2024;[Epub] CrossRef - You get what you test for: The killing effect of phage lysins is highly dependent on buffer tonicity and ionic strength
Roberto Vázquez, Diana Gutiérrez, Zoë Dezutter, Bjorn Criel, Philippe de Groote, Yves Briers
Microbial Biotechnology.2024;[Epub] CrossRef - Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria
Fazal Mehmood Khan, Fazal Rasheed, Yunlan Yang, Bin Liu, Rui Zhang
Frontiers in Pharmacology.2024;[Epub] CrossRef - Characterization of Three Different Endolysins Effective against Gram-Negative Bacteria
Tae-Hwan Jeong, Hye-Won Hong, Min Soo Kim, Miryoung Song, Heejoon Myung
Viruses.2023; 15(3): 679. CrossRef - Design strategies for positively charged endolysins: Insights into Artilysin development
Jose Vicente Carratalá, Anna Arís, Elena Garcia-Fruitós, Neus Ferrer-Miralles
Biotechnology Advances.2023; 69: 108250. CrossRef
- Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model
- Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018
- David J. Lemon , Matthew K. Kay , James K. Titus , April A. Ford , Wen Chen , LCDR Nicholas J. Hamlin , Yoon Y. Hwang
- J. Microbiol. 2019;57(6):532-538. Published online May 27, 2019
- DOI: https://doi.org/10.1007/s12275-019-8686-6
- 45 View
- 0 Download
- 23 Web of Science
- 23 Crossref
-
Abstract
-
Bacteriophage therapy was an ascendant technology for combating
bacterial infections before the golden age of antibiotics,
but the therapeutic potential of phages was largely ignored
after the discovery of penicillin. Recently, with antibioticresistant
infections on the rise, these phages are receiving renewed
attention to combat problematic bacterial infections.
Our approach is to enhance bacteriophages with antimicrobial
peptides, short peptides with broad-spectrum antibiotic or
antibiofilm effects. We inserted coding sequences for 1018,
an antimicrobial peptide previously shown to be an effective
broad-spectrum antimicrobial and antibiofilm agent, or the
fluorescent marker mCherry, into the T7Select phage genome.
Transcription and production of 1018 or mCherry began
rapidly after E. coli cultures were infected with genetically modified
phages. mCherry fluorescence, which requires a 90 min
initial maturation period, was observed in infected cultures
after 2 h of infection. Finally, we tested phages expressing 1018
(1018 T7) against bacterial planktonic cultures and biofilms,
and found the 1018 T7 phage was more effective than the
unmodified T7Select phage at both killing planktonic cells and
eradicating established biofilms, validating our phage-driven
antimicrobial peptide expression system. The combination
of narrow-spectrum phages delivering relatively high local
doses of broad-spectrum antimicrobials could be a powerful
method
to combat resistant infections. The experiments we describe prove this combination is feasible in vitro, but further testing and optimization are required before genetically modified phages are ready for use in vivo. -
Citations
Citations to this article as recorded by- Current Advances in Viral Nanoparticles for Biomedicine
Xianxun Sun, Tao Tian, Yindong Lian, Zongqiang Cui
ACS Nano.2024; 18(50): 33827. CrossRef - Intestinal Dysbiosis: Microbial Imbalance Impacts on Colorectal Cancer Initiation, Progression and Disease Mitigation
Mary Garvey
Biomedicines.2024; 12(4): 740. CrossRef - Genetically Engineered Microorganisms and Their Impact on Human Health
Marzie Mahdizade Ari, Leila Dadgar, Zahra Elahi, Roya Ghanavati, Behrouz Taheri, Marta Laranjo
International Journal of Clinical Practice.2024; 2024: 1. CrossRef - Designing a simple and efficient phage biocontainment system using the amber suppressor initiator tRNA
Pamela R. Tsoumbris, Russel M. Vincent, Paul R. Jaschke
Archives of Virology.2024;[Epub] CrossRef - Applications of designer phage encoding recombinant gene payloads
Daniel S. Schmitt, Sara D. Siegel, Kurt Selle
Trends in Biotechnology.2024; 42(3): 326. CrossRef - Identification and characterization of TatD DNase in planarian Dugesia japonica and its antibiofilm effect
Tong Yu, Zhe Sun, Xiangyu Cao, Fengtang Yang, Qiuxiang Pang, Hongkuan Deng
Environmental Research.2024; 251: 118534. CrossRef - Unraveling the potential of M13 phages in biomedicine: Advancing drug nanodelivery and gene therapy
Mahmood Fadaie, Hassan Dianat-Moghadam, Elham Ghafouri, Shamsi Naderi, Mohammad Hossein Darvishali, Mahsa Ghovvati, Hossein Khanahmad, Maryam Boshtam, Pooyan Makvandi
Environmental Research.2023; 238: 117132. CrossRef - Viruses as biomaterials
Tao Yang, Yingfan Chen, Yajing Xu, Xiangyu Liu, Mingying Yang, Chuanbin Mao
Materials Science and Engineering: R: Reports.2023; 153: 100715. CrossRef - Genetic Engineering and Biosynthesis Technology: Keys to Unlocking the Chains of Phage Therapy
Sixuan Lv, Yuhan Wang, Kaixin Jiang, Xinge Guo, Jing Zhang, Fang Zhou, Qiming Li, Yuan Jiang, Changyong Yang, Tieshan Teng
Viruses.2023; 15(8): 1736. CrossRef - Engineering therapeutic phages for enhanced antibacterial efficacy
Susanne Meile, Jiemin Du, Matthew Dunne, Samuel Kilcher, Martin J Loessner
Current Opinion in Virology.2022; 52: 182. CrossRef - Gold nanoparticle-DNA aptamer-assisted delivery of antimicrobial peptide effectively inhibits Acinetobacter baumannii infection in mice
Jaeyeong Park, Eunkyoung Shin, Ji-Hyun Yeom, Younkyung Choi, Minju Joo, Minho Lee, Je Hyeong Kim, Jeehyeon Bae, Kangseok Lee
Journal of Microbiology.2022; 60(1): 128. CrossRef - How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections
Aditi Singh, Sudhakar Padmesh, Manish Dwivedi, Irena Kostova
Infection and Drug Resistance.2022; Volume 15: 503. CrossRef - Comparative Analysis of NanoLuc Luciferase and Alkaline Phosphatase Luminescence Reporter Systems for Phage-Based Detection of Bacteria
Shalini Wijeratne, Arindam Bakshi, Joey Talbert
Bioengineering.2022; 9(9): 479. CrossRef - Construction and Characterization of T7 Bacteriophages Harboring Apidaecin-Derived Sequences
Tobias Ludwig, Ralf Hoffmann, Andor Krizsan
Current Issues in Molecular Biology.2022; 44(6): 2554. CrossRef - Genetic and Chemical Engineering of Phages for Controlling Multidrug-Resistant Bacteria
Dingming Guo, Jingchao Chen, Xueyang Zhao, Yanan Luo, Menglu Jin, Fenxia Fan, Chaiwoo Park, Xiaoman Yang, Chuqing Sun, Jin Yan, Weihua Chen, Zhi Liu
Antibiotics.2021; 10(2): 202. CrossRef - Antibiofilm activity of host defence peptides: complexity provides opportunities
Robert E. W. Hancock, Morgan A. Alford, Evan F. Haney
Nature Reviews Microbiology.2021; 19(12): 786. CrossRef - Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response?
Mwila Kabwe, Stuart Dashper, Gilad Bachrach, Joseph Tucci
FEMS Microbiology Reviews.2021;[Epub] CrossRef - Bacterial Biofilm Destruction: A Focused Review On The Recent Use of Phage-Based Strategies With Other Antibiofilm Agents
Stephen Amankwah, Kedir Abdusemed, Tesfaye Kassa
Nanotechnology, Science and Applications.2021; Volume 14: 161. CrossRef - Antibiotic Replacement Therapy: Phage Therapy
宇波 向
Advances in Microbiology.2021; 10(01): 30. CrossRef - Phages for Biofilm Removal
Celia Ferriol-González, Pilar Domingo-Calap
Antibiotics.2020; 9(5): 268. CrossRef - Phage therapy with mycobacteriophage as an alternative against antibiotic resistance produced by Mycobacterium tuberculosis
Pamela Rodríguez H, Angie Changuán C, Lizbeth X. Quiroz
Bionatura.2020; 5(1): 1078. CrossRef - The Principles, Mechanisms, and Benefits of Unconventional Agents in the Treatment of Biofilm Infection
Jasminka Talapko, Ivana Škrlec
Pharmaceuticals.2020; 13(10): 299. CrossRef - Bacterial Virus Lambda Gpd-Fusions to Cathelicidins, α- and β-Defensins, and Disease-Specific Epitopes Evaluated for Antimicrobial Toxicity and Ability to Support Phage Display
Sidney Hayes
Viruses.2019; 11(9): 869. CrossRef
- Current Advances in Viral Nanoparticles for Biomedicine
First
Prev
TOP
